Overview

Staccato Loxapine Thorough QT/QTc Study

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.
Phase:
Phase 1
Details
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Treatments:
Loxapine
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination